KR20030007589A - 알레르기성 질환 치료에 유용한 디설파이드 유도체 - Google Patents
알레르기성 질환 치료에 유용한 디설파이드 유도체 Download PDFInfo
- Publication number
- KR20030007589A KR20030007589A KR1020027014929A KR20027014929A KR20030007589A KR 20030007589 A KR20030007589 A KR 20030007589A KR 1020027014929 A KR1020027014929 A KR 1020027014929A KR 20027014929 A KR20027014929 A KR 20027014929A KR 20030007589 A KR20030007589 A KR 20030007589A
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- substituted
- substituent
- cycloalkyl
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000002019 disulfides Chemical class 0.000 title claims abstract description 24
- 208000026935 allergic disease Diseases 0.000 title claims abstract description 16
- 210000001508 eye Anatomy 0.000 claims abstract description 10
- 210000004072 lung Anatomy 0.000 claims abstract description 6
- 210000003491 skin Anatomy 0.000 claims abstract description 6
- 201000008736 Systemic mastocytosis Diseases 0.000 claims abstract description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 5
- 125000001424 substituent group Chemical group 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 19
- 125000003342 alkenyl group Chemical group 0.000 claims description 16
- 125000003545 alkoxy group Chemical group 0.000 claims description 16
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 16
- 229910052736 halogen Inorganic materials 0.000 claims description 16
- 150000002367 halogens Chemical class 0.000 claims description 16
- 125000003107 substituted aryl group Chemical group 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 230000000699 topical effect Effects 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 3
- 210000005069 ears Anatomy 0.000 claims description 2
- 210000001331 nose Anatomy 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 210000003630 histaminocyte Anatomy 0.000 abstract description 12
- 238000011282 treatment Methods 0.000 abstract description 10
- 230000002265 prevention Effects 0.000 abstract description 5
- 239000003381 stabilizer Substances 0.000 abstract description 5
- GUUVPOWQJOLRAS-UHFFFAOYSA-N Diphenyl disulfide Chemical class C=1C=CC=CC=1SSC1=CC=CC=C1 GUUVPOWQJOLRAS-UHFFFAOYSA-N 0.000 abstract 1
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 239000000872 buffer Substances 0.000 description 8
- 229960001340 histamine Drugs 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 229940125715 antihistaminic agent Drugs 0.000 description 4
- 239000000739 antihistaminic agent Substances 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000011200 topical administration Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 208000002205 allergic conjunctivitis Diseases 0.000 description 3
- 229960000686 benzalkonium chloride Drugs 0.000 description 3
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 238000007910 systemic administration Methods 0.000 description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 239000003732 agents acting on the eye Substances 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 208000024998 atopic conjunctivitis Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000000850 decongestant Substances 0.000 description 2
- 229940124581 decongestants Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 2
- 229940124274 edetate disodium Drugs 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229940054534 ophthalmic solution Drugs 0.000 description 2
- 239000002997 ophthalmic solution Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- BYJAVTDNIXVSPW-UHFFFAOYSA-N tetryzoline Chemical compound N1CCN=C1C1C2=CC=CC=C2CCC1 BYJAVTDNIXVSPW-UHFFFAOYSA-N 0.000 description 2
- -1 triethylamine Chemical class 0.000 description 2
- YYYOQURZQWIILK-UHFFFAOYSA-N 2-[(2-aminophenyl)disulfanyl]aniline Chemical compound NC1=CC=CC=C1SSC1=CC=CC=C1N YYYOQURZQWIILK-UHFFFAOYSA-N 0.000 description 1
- 206010049153 Allergic sinusitis Diseases 0.000 description 1
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010018258 Giant papillary conjunctivitis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- HXBPYFMVGFDZFT-UHFFFAOYSA-N allyl isocyanate Chemical compound C=CCN=C=O HXBPYFMVGFDZFT-UHFFFAOYSA-N 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 229940124623 antihistamine drug Drugs 0.000 description 1
- 229940127217 antithrombotic drug Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229960004574 azelastine Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003112 degranulating effect Effects 0.000 description 1
- 229960001271 desloratadine Drugs 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- PIZLBWGMERQCOC-UHFFFAOYSA-N dibenzyl carbonate Chemical compound C=1C=CC=CC=1COC(=O)OCC1=CC=CC=C1 PIZLBWGMERQCOC-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229960000325 emedastine Drugs 0.000 description 1
- KBUZBQVCBVDWKX-UHFFFAOYSA-N emedastine Chemical compound N=1C2=CC=CC=C2N(CCOCC)C=1N1CCCN(C)CC1 KBUZBQVCBVDWKX-UHFFFAOYSA-N 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002388 eustachian tube Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 229960003592 fexofenadine Drugs 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 201000010666 keratoconjunctivitis Diseases 0.000 description 1
- 229960004958 ketotifen Drugs 0.000 description 1
- 229960001828 levocabastine hydrochloride Drugs 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 229960001798 loteprednol Drugs 0.000 description 1
- YPZVAYHNBBHPTO-MXRBDKCISA-N loteprednol Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)OCCl)[C@@H]4[C@@H]3CCC2=C1 YPZVAYHNBBHPTO-MXRBDKCISA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960001664 mometasone Drugs 0.000 description 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940125702 ophthalmic agent Drugs 0.000 description 1
- 229940100655 ophthalmic gel Drugs 0.000 description 1
- 229940023490 ophthalmic product Drugs 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
- 229960000395 phenylpropanolamine Drugs 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- WHALSQRTWNBBCV-UHFFFAOYSA-N s-aminosulfanylthiohydroxylamine Chemical compound NSSN WHALSQRTWNBBCV-UHFFFAOYSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229960000337 tetryzoline Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
- C07C323/43—Y being a hetero atom
- C07C323/44—X or Y being nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20582700P | 2000-05-19 | 2000-05-19 | |
| US60/205,827 | 2000-05-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20030007589A true KR20030007589A (ko) | 2003-01-23 |
Family
ID=22763799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020027014929A Withdrawn KR20030007589A (ko) | 2000-05-19 | 2001-04-25 | 알레르기성 질환 치료에 유용한 디설파이드 유도체 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US6492552B2 (enExample) |
| EP (1) | EP1282599B1 (enExample) |
| JP (1) | JP2003534318A (enExample) |
| KR (1) | KR20030007589A (enExample) |
| CN (2) | CN1175807C (enExample) |
| AR (1) | AR028566A1 (enExample) |
| AT (1) | ATE330938T1 (enExample) |
| AU (2) | AU2001255675B2 (enExample) |
| BR (1) | BR0110943A (enExample) |
| CA (1) | CA2407964A1 (enExample) |
| CY (1) | CY1105164T1 (enExample) |
| DE (1) | DE60120961T2 (enExample) |
| DK (1) | DK1282599T3 (enExample) |
| ES (1) | ES2261402T3 (enExample) |
| MX (1) | MXPA02011481A (enExample) |
| PL (1) | PL365457A1 (enExample) |
| PT (1) | PT1282599E (enExample) |
| WO (1) | WO2001090060A1 (enExample) |
| ZA (1) | ZA200208840B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1173697C (zh) * | 2000-05-19 | 2004-11-03 | 爱尔康公司 | 用于治疗过敏性疾病的苯胺二硫化物衍生物 |
| US7645903B2 (en) | 2002-10-31 | 2010-01-12 | Ge Healthcare Bio-Sciences Ab | Use of urea variants as affinity ligands |
| AU2005259911A1 (en) * | 2004-06-28 | 2006-01-12 | Alcon, Inc. | Topical formulations for treating allergic diseases |
| WO2006069282A2 (en) * | 2004-12-22 | 2006-06-29 | California Institute Of Technology | Degradable p0lymers and methods of preparation thereof |
| US20130011378A1 (en) | 2011-06-17 | 2013-01-10 | Tzung-Horng Yang | Stable formulations of a hyaluronan-degrading enzyme |
| KR20140043438A (ko) * | 2011-06-17 | 2014-04-09 | 할로자임, 아이엔씨 | 히알루로난 분해 효소의 안정한 제형 |
| FR3057264B1 (fr) * | 2016-10-12 | 2020-05-29 | Arkema France | Composes porteurs de groupes associatifs azotes |
| CN108586299B (zh) * | 2018-06-06 | 2020-06-16 | 北京化工大学 | 一种可引发、聚合及降低体积收缩的芳香二硫化合物的制备方法及用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1232787A (enExample) | 1967-08-08 | 1971-05-19 | ||
| US3663616A (en) | 1969-10-13 | 1972-05-16 | Sherwin Williams Co | Bis(2-carbamylphenyl)disulfides |
| EP0006227B1 (en) | 1978-06-16 | 1984-12-27 | Kyowa Hakko Kogyo Co., Ltd | Antithrombotic pharmaceutical preparation containing 2,2'-dithiobis benzamide derivatives and new 2,2'-dithiobis benzamide derivatives |
| US4923892A (en) | 1985-08-17 | 1990-05-08 | Burroughs Wellcome Co. | Tricyclic aromatic compounds |
| GB8520662D0 (en) | 1985-08-17 | 1985-09-25 | Wellcome Found | Tricyclic aromatic compounds |
| JPS6310784A (ja) | 1986-03-03 | 1988-01-18 | Kyowa Hakko Kogyo Co Ltd | 抗アレルギー剤 |
| GB9020933D0 (en) | 1990-09-26 | 1990-11-07 | Ici Plc | Compound,preparation and use |
| US5859017A (en) | 1994-04-01 | 1999-01-12 | Cell Therapeutics, Inc. | Method for inhibiting mast cell and basophil activation |
| US5463122A (en) | 1994-08-05 | 1995-10-31 | Warner-Lambert Company | Arylthio compounds |
| US5734081A (en) | 1994-08-05 | 1998-03-31 | Warner-Lambert Company | Arylthio compounds |
| US6001555A (en) | 1994-09-23 | 1999-12-14 | The United States Of America As Represented By The Department Of Health And Human Services | Method for identifying and using compounds that inactivate HIV-1 and other retroviruses by attacking highly conserved zinc fingers in the viral nucleocapsid protein |
| JPH095926A (ja) * | 1995-04-18 | 1997-01-10 | Fuji Photo Film Co Ltd | 熱現像感光材料 |
| US5641805A (en) | 1995-06-06 | 1997-06-24 | Alcon Laboratories, Inc. | Topical ophthalmic formulations for treating allergic eye diseases |
| US6225327B1 (en) | 1996-04-18 | 2001-05-01 | Alcon Laboratories, Inc. | Compounds which inhibit human conjunctival mast cell degranulation for treating ocular allergic-type complications |
| JP2894445B2 (ja) | 1997-02-12 | 1999-05-24 | 日本たばこ産業株式会社 | Ｃｅｔｐ活性阻害剤として有効な化合物 |
| JP3940201B2 (ja) | 1997-05-20 | 2007-07-04 | 大塚製薬株式会社 | ３，３’−ジチオジベンゾヒドロキサム酸 |
-
2001
- 2001-04-25 MX MXPA02011481A patent/MXPA02011481A/es active IP Right Grant
- 2001-04-25 CN CNB018094775A patent/CN1175807C/zh not_active Expired - Fee Related
- 2001-04-25 CN CNB200410073926XA patent/CN1241912C/zh not_active Expired - Fee Related
- 2001-04-25 PL PL01365457A patent/PL365457A1/xx not_active Application Discontinuation
- 2001-04-25 AU AU2001255675A patent/AU2001255675B2/en not_active Ceased
- 2001-04-25 DE DE60120961T patent/DE60120961T2/de not_active Expired - Fee Related
- 2001-04-25 KR KR1020027014929A patent/KR20030007589A/ko not_active Withdrawn
- 2001-04-25 AU AU5567501A patent/AU5567501A/xx active Pending
- 2001-04-25 CA CA002407964A patent/CA2407964A1/en not_active Abandoned
- 2001-04-25 AT AT01928863T patent/ATE330938T1/de not_active IP Right Cessation
- 2001-04-25 US US09/841,859 patent/US6492552B2/en not_active Expired - Fee Related
- 2001-04-25 WO PCT/US2001/013331 patent/WO2001090060A1/en not_active Ceased
- 2001-04-25 BR BR0110943-0A patent/BR0110943A/pt not_active IP Right Cessation
- 2001-04-25 JP JP2001586249A patent/JP2003534318A/ja not_active Ceased
- 2001-04-25 PT PT01928863T patent/PT1282599E/pt unknown
- 2001-04-25 EP EP01928863A patent/EP1282599B1/en not_active Expired - Lifetime
- 2001-04-25 DK DK01928863T patent/DK1282599T3/da active
- 2001-04-25 ES ES01928863T patent/ES2261402T3/es not_active Expired - Lifetime
- 2001-05-15 AR ARP010102303A patent/AR028566A1/es not_active Application Discontinuation
-
2002
- 2002-05-22 US US10/152,646 patent/US6500864B1/en not_active Expired - Fee Related
- 2002-05-22 US US10/153,716 patent/US6506802B2/en not_active Expired - Fee Related
- 2002-10-31 ZA ZA200208840A patent/ZA200208840B/en unknown
-
2006
- 2006-08-23 CY CY20061101174T patent/CY1105164T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR028566A1 (es) | 2003-05-14 |
| HK1050185A1 (en) | 2003-06-13 |
| CN1241912C (zh) | 2006-02-15 |
| JP2003534318A (ja) | 2003-11-18 |
| DE60120961D1 (de) | 2006-08-03 |
| US6506802B2 (en) | 2003-01-14 |
| MXPA02011481A (es) | 2003-06-06 |
| AU5567501A (en) | 2001-12-03 |
| EP1282599A1 (en) | 2003-02-12 |
| WO2001090060A1 (en) | 2001-11-29 |
| US20020193634A1 (en) | 2002-12-19 |
| US20020058709A1 (en) | 2002-05-16 |
| DE60120961T2 (de) | 2006-11-16 |
| PT1282599E (pt) | 2006-08-31 |
| EP1282599B1 (en) | 2006-06-21 |
| PL365457A1 (en) | 2005-01-10 |
| US6500864B1 (en) | 2002-12-31 |
| DK1282599T3 (da) | 2006-07-31 |
| ATE330938T1 (de) | 2006-07-15 |
| CY1105164T1 (el) | 2010-03-03 |
| CN1429209A (zh) | 2003-07-09 |
| AU2001255675B2 (en) | 2005-04-14 |
| CN1616422A (zh) | 2005-05-18 |
| US20020193633A1 (en) | 2002-12-19 |
| US6492552B2 (en) | 2002-12-10 |
| BR0110943A (pt) | 2004-01-06 |
| CA2407964A1 (en) | 2001-11-29 |
| ZA200208840B (en) | 2003-12-02 |
| CN1175807C (zh) | 2004-11-17 |
| ES2261402T3 (es) | 2006-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6492552B2 (en) | Disulfide derivatives useful for treating allergic diseases | |
| US6452052B1 (en) | Aniline disulfide derivatives for treating allergic diseases | |
| AU2001255675A1 (en) | Disulfide derivatives useful for treating allergic diseases | |
| AU2001257227A1 (en) | Aniline Disulfide Derivatives for Treating Allergic Diseases | |
| US6492418B2 (en) | Compositions containing a benzamide disulfide derivative for treating allergic diseases | |
| AU2001253807A1 (en) | Compositions containing a benzamide disulfide derivative for treating allergic diseases | |
| HK1050185B (en) | Disulfide derivatives useful for treating allergic diseases | |
| HK1050677B (en) | Aniline disulfide derivatives for treating allergic diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20021107 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |